TmBU chemo before stem cell transplant for high-risk leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This clinical trial tests a new combination of chemotherapy drugs (called TmBU) before a stem cell transplant for people with high-risk or relapsed acute leukemia. The goal is to see if this conditioning regimen works better and is safe for patients who need a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that is high-risk, has come back after treatment, or is not responding to standard therapy.
- Your age should be between 15 and 65 years old.
- Your heart, kidneys, and liver must be working well enough for a stem cell transplant.
- You should not have an active infection like HIV, hepatitis B or C, or uncontrolled other infections.
- You must not have another cancer that was treated in the last 3 years, and you should not have serious brain or nerve conditions like seizures or stroke.
- You should be willing to use contraception if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (SHR2554 and azacitidine) given before a stem cell transplant for people with high-risk or relapsed leukemia or MDS. The goal is to see if this approach can help make the transplant more effective and reduce the chance of the disease coming back.
This trial tests a combination of a new drug (SHR2554) with another medication (azacitidine) and a conditioning regimen before a stem cell transplant. It aims to improve outcomes for high-risk or relapsed leukemia and MDS patients.
This trial tests a combination of two chemotherapy drugs given before a stem cell transplant to help people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. The goal is to improve the success of the transplant.
This trial tests a special combination of chemotherapy drugs (called a conditioning regimen) given before a half-matched stem cell transplant for older adults with acute myeloid leukemia (AML) in their first remission. The goal is to make the transplant safer and more effective for people aged 55 to 75.
This trial is testing a more targeted way to deliver radiation before a stem cell transplant, aiming to reduce side effects while helping the new cells engraft. It includes two different radiation doses, one for first-time transplant patients and another for those who have relapsed after a prior transplant.
This trial compares two chemotherapy conditioning regimens (BuCy and TBICy) used before a stem cell transplant for patients with T-cell acute lymphoblastic leukemia. The goal is to see which regimen leads to better outcomes after the transplant.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.